Mahima Datla has emerged as one of the biggest names in the pharmaceutical sector in India. As the Managing Director of Biological E. Limited, one of India’s largest vaccine manufacturers, she has contributed immensely to public health. With a far-sighted vision, relentless drive for innovation, and strong leadership, she has transformed her company while addressing global health challenges. She is widely recognized for her professional achievements and rising net worth, reflecting the industry’s respect for her.
Early Life and Education
Mahima Datla was born on 18th August 1980 in an environment closely connected to medicine. Her father, Vijay Kumar Datla, played a significant role in exposing her to the healthcare sector from a young age. Driven by a desire to prepare herself for leadership, she went abroad to study. She pursued Business Administration at University College London and later completed an MBA from the University of California, Berkeley. This combination of academic and practical experience laid a strong foundation for her entrepreneurial journey.
Professional Journey and Leadership
Mahima gained cross-departmental experience at Biological E., working in research, product development, and strategic planning. Her ability to envision and operate within a business framework gradually prepared her to lead the company. In 2018, she was appointed Managing Director, marking a significant turning point for the company. Under her leadership, Biological E. shifted focus from general medicine products to vaccine development. Today, it is recognized as a low-cost vaccine manufacturer playing a key role in both Indian and global markets.
Crucial Achievements and Contributions
Development of Corbevax
One of Mahima’s hallmark achievements is leading the development of Corbevax, India’s first indigenous COVID-19 vaccine. Unlike costlier vaccines worldwide, Corbevax was produced at a fraction of the cost, providing life-saving doses to millions.
Global Collaboration
Under her guidance, Biological E. collaborates with UNICEF, GAVI, and WHO to deliver vaccines to underserved populations, reflecting her commitment to health equity.
Modern Manufacturing
Mahima has heavily invested in state-of-the-art manufacturing facilities, enhancing the company’s capacity and efficiency. These advancements enable Biological E. to respond swiftly to global health emergencies.
Advocacy for Women and Public Health
Being a woman in a male-dominated industry, Mahima actively promotes gender inclusivity and encourages women to take leadership roles. She also supports initiatives that foster diversity within healthcare. Biological E. remains a prominent contributor to India’s National Immunization Program.
Awards and Recognition
Mahima Datla’s pioneering achievements in innovation and leadership have established her as a global healthcare leader. She has been recognized as the richest woman in Andhra Pradesh and Telangana.
Net Worth
As of 2024, Mahima Datla’s net worth is approximately USD 3.3 billion (≈ ₹27,000 crore). The majority of her wealth comes from her holding and leadership in Biological E. Limited, which has grown rapidly under her stewardship. With strong revenue streams from both domestic and international vaccine demand, her fortune is expected to grow further.
About the Author
